Remove FDA Compliance Remove Marketing Remove Regulations
article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog: Biosimilars

Four of the letters addressed failure to comply with drug Current Good Manufacturing Practice regulations, four more stated that the recipients were distributing unapproved drug products, two alleged violations of the Quality System Regulation by medical device manufacturers, and one was addressed to a clinical investigator.

FDA 59
article thumbnail

Healthcare Cloud Adoption & How It Can Impact Medtech Sales

H1 Blog

MarketsandMarkets projects the global healthcare cloud computing market, with North America leading the way, will grow from $19.46 Prove & Facilitate HIPAA & FDA Compliance Another facet of healthcare cloud technology that could impact sales is compliance with HIPAA and FDA regulations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Dealing with the Pennsylvania Supreme Court’s Non-Decision on Standards Compliance Evidence

Drug & Device Law

It is not evidence of the underlying attributes of the product that make it compliant with regulations or standards, which is presumably admissible subject to the ordinary Rules of Evidence. A plaintiff’s pursuit of such theories thus should allow admission of standards compliance evidence. Central Medical Health Services, Inc. ,

article thumbnail

A Thorny PMA Preemption Decision from Rhode Island

Drug & Device Law

It involves allegations against the manufacturer and distributor of surgical clips used in tubal ligation surgery—Class III Pre-Market Approved (“PMA”) medical devices. Coopersurgical, Inc. 2024 WL 1109055 (D.R.I. 14, 2024). Plaintiff had surgery in 2014 in which the clips were used. at 731, based on a pre- Riegel decision, Hodges v.

FDA 52
article thumbnail

Perfect Defense §510(k) Compliance Win in New Jersey May Be Pyrrhic

Drug & Device Law

It was thus “unfair for the trial court not to allow [defendant] to explain in response that it received 510(k) clearance to market the devices without clinical studies or trials.” pursuant to conditions established by the federal Food and Drug Administration and applicable regulations, including. . . labeling regulations.